RAS Pathway Mutations and Therapeutics in Vascular Anomalies
Sara Alharbi(Cincinnati Children's Hospital Medical Center), Timothy D. Le Cras(Cincinnati Children's Hospital Medical Center), Svatava Merkle(Cincinnati Children's Hospital Medical Center), Andrew M. Waters(University of North Carolina at Chapel Hill), Adrienne M. Hammill(Cincinnati Children's Hospital Medical Center)
Cited by 11
Related Papers
Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic Cancer
|Cancer Research|2022|160
Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham–Stout disease
|Pediatric Blood & Cancer|2019|126
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
|Cell Reports|2020|108
Inhibition of PI3K by PX-866 Prevents Transforming Growth Factor-α–Induced Pulmonary Fibrosis
|American Journal Of Pathology|2009|62